Spero Health - Indianapolis

Spero Health - Indianapolis is an addiction-treatment facility located in Lexington, KY. The facility's programming is outpatient (Outpatient, MAT), not residential. What follows is an orientation — not a review — to the practical questions worth asking before admission.

Care levels at Spero Health - Indianapolis

The care-level question matters because what a facility offers is what it can realistically treat well. Spero Health - Indianapolis is an outpatient-focused program (Outpatient, MAT) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. Before admission, an independent clinical assessment (from a primary-care doctor, licensed substance-use counselor, or addiction-medicine physician) can confirm whether Spero Health - Indianapolis's offerings match the clinical need.

Insurance and payment

On insurance specifically: Spero Health - Indianapolis accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. The facility also accepts TRICARE or military benefits. Before admission, ask the facility's utilization-review team for a written Verification of Benefits — not verbal assurance, which is where most post-treatment financial surprises come from. Also ask for specific plan-level confirmation, not carrier-level (e.g., "your Aetna PPO plan" not just "Aetna").

Specialty programming

The facility's documented specialty programming includes: Adult women, Pregnant/postpartum women, Adult men. Specialty programming varies substantially by facility — some facilities offer "dual diagnosis" as a marketing category but not a clinical differentiator. Ask for the specific clinical-team credentials and the actual hours of specialty-specific content per week.

Before you call

Before admission to Spero Health - Indianapolis, three questions consistently produce the most useful information: (1) which ASAM level of care are you treating me at, and what is the clinical rationale; (2) can you send me a written Verification of Benefits for my specific insurance plan; (3) what is your policy on medication-assisted treatment for opioid use disorder — specifically, do you continue patients on buprenorphine or methadone during residential programming. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation.